Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUILLICHEW ER vs ADDERALL 7.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.
ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.
Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).
5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.
The terminal elimination half-life of methylphenidate is approximately 3-4 hours in children and 3.5-5 hours in adults. For Quilli Chew ER, the extended-release formulation provides a prolonged absorption phase, with an effective duration of action of up to 12 hours.
The terminal elimination half-life of amphetamine is approximately 10-13 hours in adults, but can vary based on urinary p H (alkaline urine prolongs half-life up to 20 hours; acidic urine reduces it to 7-8 hours). In children, half-life is slightly shorter (6-8 hours). Clinical context: Steady-state is achieved within 2-3 days.
Methylphenidate is primarily metabolized by deesterification via carboxylesterase 1 (CES1) to ritalinic acid, which is pharmacologically inactive. Minor metabolism via hydroxylation and microsomal oxidation.
Amphetamine and dextroamphetamine are metabolized primarily in the liver via oxidative deamination and aromatic hydroxylation. The major metabolic pathway involves the enzyme CYP2D6, which converts amphetamine to 4-hydroxyamphetamine and norephedrine. Other minor pathways include N-dealkylation and deamination.
Quilli Chew ER (methylphenidate extended-release chewable tablet) is primarily eliminated via renal excretion as metabolites (60-80%) and unchanged drug (approx. 10%). Hepatic metabolism accounts for the remainder. Fecal elimination is minimal.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites (including deaminated and hydroxylated products). Fecal excretion is negligible (<5%).
Methylphenidate is approximately 10-33% bound to plasma proteins, primarily albumin. Binding is low and not clinically significant.
Approximately 20-25% bound to plasma proteins (primarily albumin).
Volume of distribution (Vd) for methylphenidate is approximately 2-3 L/kg, indicating extensive tissue distribution. It is not highly bound to tissues.
Apparent volume of distribution is approximately 3-4 L/kg, indicating extensive tissue distribution, with high concentrations in the brain and cerebrospinal fluid.
Oral bioavailability of methylphenidate is variable and low, approximately 11-52% due to extensive first-pass metabolism. Quilli Chew ER is designed to deliver a consistent extended-release profile with a bioavailability of about 20-30% relative to immediate-release formulations.
Oral bioavailability is approximately 75-80% for immediate-release formulations, with no significant food effect. Extended-release capsules have similar bioavailability when taken intact.
No dosage adjustment recommended for GFR >30 m L/min; avoid in GFR ≤30 m L/min.
e GFR 30-89 m L/min: Administer 50% of usual dose; e GFR <30 m L/min: Not recommended due to accumulation; Hemodialysis: Not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended.
Child-Pugh Class A: No adjustment necessary; Child-Pugh Class B: Reduce dose by 50%; Child-Pugh Class C: Not recommended.
Children ≥6 years: initial 20 mg orally once daily, titrate by 10 mg weekly to max 60 mg/day.
Children ≥3 years (ADHD): Immediate-release: Starting dose 2.5 mg once or twice daily, increase by 2.5-5 mg/day weekly to max 40 mg/day in divided doses; Extended-release: ≥6 years: Starting 10 mg once daily, increase by 5-10 mg weekly to max 30 mg/day. Weight <30 kg: Use lower end of dosing range.
Start at 10 mg orally once daily, titrate cautiously; monitor for increased sensitivity and cardiovascular effects.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg at weekly intervals; maximum 40 mg/day; monitor for cardiovascular effects, insomnia, and appetite suppression.
QUILLICHEW ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including ADDERALL, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; monitor closely.,Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, or aggressive behavior.,Long-term suppression of growth (weight and height) in pediatric patients.,Seizures: use with caution in patients with history of seizures.,Priapism: prolonged, painful erections may occur.,Peripheral vasculopathy: Raynaud's phenomenon.
Serious Cardiovascular Events: Sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing structural cardiac abnormalities.,Blood Pressure and Heart Rate Increases: Monitor heart rate and blood pressure; use caution in patients with hypertension or tachycardia.,Psychiatric Adverse Events: May exacerbate pre-existing psychosis, mania, or cause new psychotic/manic symptoms.,Seizures: May lower seizure threshold; use with caution in patients with a history of seizures.,Peripheral Vasculopathy: Including Raynaud's phenomenon; monitor for digital changes.,Serotonin Syndrome: Risk when co-administered with serotonergic drugs.,Growth Suppression: Monitor growth in pediatric patients during treatment.,Abuse and Dependence: High potential; prescribe cautiously and monitor for misuse.
Known hypersensitivity to methylphenidate or any component of the formulation.,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy.,Glaucoma.,Motor tics or family history of Tourette's syndrome.,Severe anxiety, tension, or agitation.,Patients with history of drug abuse or dependence.
Hypersensitivity to amphetamines or any components of the formulation,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Symptomatic cardiovascular disease,Moderate to severe hypertension,Advanced arteriosclerosis
Avoid high-fat meals as they may delay absorption and alter peak concentration. Grapefruit and grapefruit juice may increase methylphenidate levels and should be avoided. Acidic foods (e.g., citrus fruits, colas) can affect drug absorption; maintain a consistent dietary pattern. Alcohol may cause dose dumping and should be avoided.
Take with or without food, but consistency is recommended to avoid fluctuating absorption. Avoid acidic foods or large amounts of vitamin C (e.g., citrus fruits, juices) within 1 hour of dosing, as they can decrease absorption. Avoid high-fat meals which can delay absorption. Grapefruit and grapefruit juice may increase amphetamine levels; limit or avoid.
Pregnancy Category C. First trimester: Possible increased risk of cardiovascular malformations and oral clefts from methylphenidate exposure; however, absolute risk remains low. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (including irritability, dysphoria, and poor feeding).
Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac, oral clefts) based on amphetamine class; insufficient human data. Second/third trimester: Risk of preterm delivery, low birth weight, and neonatal withdrawal (e.g., irritability, poor feeding).
Limited data. Methylphenidate is excreted into breast milk. M/P ratio not established. Infant relative dose <1% of maternal weight-adjusted dose. Monitor infant for agitation, insomnia, and poor weight gain. Avoid use in breastfeeding unless clearly necessary.
Amphetamines are excreted into breast milk. M/P ratio unknown. Potential for infant stimulation, insomnia, and growth suppression. Breastfeeding not recommended during therapy.
Physiologic changes in pregnancy (increased plasma volume, renal clearance, and hepatic metabolism) may reduce methylphenidate levels. Consider increasing dose based on clinical response and tolerability, with gradual titration. Monitor for reduced efficacy in second and third trimesters. Use lowest effective dose.
Decreased plasma levels due to increased volume of distribution and hepatic metabolism; dose may need to be increased, but risk-benefit must be evaluated. Use lowest effective dose with close monitoring.
QUILLICHEW ER is an extended-release formulation of methylphenidate, a CNS stimulant, indicated for ADHD. Chewing or crushing the tablet destroys the extended-release mechanism, risking dose dumping. The tablet shell may appear in stool but is not medically significant. Monitor for growth suppression in children, weight loss, and potential for abuse. Avoid use in patients with glaucoma, motor tics, or family history of Tourette's syndrome. Use caution in patients with hypertension, tachycardia, or pre-existing psychiatric disorders like bipolar disorder or psychosis. Assess for potential drug interactions, particularly with MAOIs, anticoagulants (may decrease effect), and vasopressors.
Adderall 7.5 mg is a combination of amphetamine salts (dextroamphetamine and levoamphetamine) in a 3:1 ratio. It is a CNS stimulant indicated for ADHD and narcolepsy. Monitor for cardiovascular effects (BP, HR) prior to and during therapy. Use with caution in patients with hypertension, tachyarrhythmias, or history of substance abuse. Avoid concomitant use with MAOIs or within 14 days of discontinuation. May cause growth suppression in children; monitor height and weight. Abuse potential is high; prescribe the smallest effective dose and use tamper-resistant formulations when possible.
Take exactly as prescribed. Do not chew, crush, or split the tablet; swallow whole with liquid.,The tablet shell may appear in your stool, but the medication is absorbed; this is normal.,Do not take in the evening to prevent insomnia. Take in the morning with or without food.,Avoid alcohol while taking this medication; alcohol can affect the extended-release properties.,Common side effects include decreased appetite, trouble sleeping, dry mouth, and headache.,Report any chest pain, shortness of breath, fainting, or severe dizziness immediately.,Store at room temperature, protect from moisture, and keep out of reach of children.,Your doctor will monitor your blood pressure, heart rate, and weight regularly.,Do not stop abruptly; tapering may be needed to avoid withdrawal or rebound depression.
Take exactly as prescribed; do not take more or more often than directed.,Swallow tablets whole; do not crush, chew, or break them.,Avoid taking late in the day to prevent insomnia.,Do not stop abruptly; sudden discontinuation can cause severe fatigue and depression.,Notify your doctor of any history of heart problems, high blood pressure, seizures, or mental health conditions.,Report any chest pain, shortness of breath, fainting, or seizures immediately.,Avoid alcohol and marijuana; they can increase side effects.,Store at room temperature away from moisture and heat.,Keep out of reach of children; this medication has a high risk of overdose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUILLICHEW ER vs ADDERALL 7.5, answered by our medical review team.
QUILLICHEW ER is a CNS Stimulant that works by Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.. ADDERALL 7.5 is a CNS Stimulant that works by ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUILLICHEW ER and ADDERALL 7.5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUILLICHEW ER is: Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).. The standard adult dose of ADDERALL 7.5 is: 5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUILLICHEW ER and ADDERALL 7.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUILLICHEW ER is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of cardiovascular malformations and oral clefts from methylphenidate exposure; however, absolute risk remains low. Se. ADDERALL 7.5 is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac, oral clefts) based on amphetamine class; insufficient human data. Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.